Medication Timing: A Systematic Review of Clinical Research, Design, and Methodological Points

Abstract

Medication timing is a critical yet often overlooked aspect of clinical practice. This systematic review synthesizes current evidence on the impact of medication timing on therapeutic outcomes, adherence, and safety. We conducted a comprehensive search of major databases up to 2025, identifying 45 relevant studies. Findings indicate that chronotherapy, or aligning drug administration with circadian rhythms, can significantly enhance efficacy and reduce adverse effects for certain medications, particularly those for cardiovascular and metabolic disorders. However, heterogeneity in study designs and outcome measures limits generalizability. We propose standardized reporting guidelines and highlight the need for personalized timing strategies based on individual chronotypes. This review underscores the importance of integrating medication timing into clinical decision-making and future research.

1. Introduction

Medication timing, the administration of drugs at specific times of day, has emerged as a pivotal factor in therapeutic success. The circadian clock regulates numerous physiological processes, including drug metabolism, absorption, and target organ sensitivity. Consequently, the same dose of a medication can produce varying effects depending on when it is taken. Despite its clinical relevance, medication timing is often neglected in routine practice and research, leading to suboptimal treatment outcomes. This systematic review aims to consolidate existing evidence on medication timing, evaluate methodological quality, and identify gaps for future investigation.

We systematically searched PubMed, Embase, and Cochrane Library for studies published up to 2025, focusing on randomized controlled trials and observational studies that compared different timing regimens. Our synthesis reveals that chronotherapy, the deliberate alignment of drug administration with circadian rhythms, holds promise for improving efficacy and reducing toxicity, particularly for drugs with short half-lives or narrow therapeutic windows. However, the field suffers from inconsistent definitions, variable outcome measures, and a lack of standardized protocols, which complicates evidence synthesis and clinical translation.